Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IASO-782 in Systemic Lupus Erythematosus
NCT07483346Phase 1Recruiting
- Sponsor
- Reindeer Biotech
- Start
- May 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IASO-782 in systemic lupus erythematosus (SLE) (2 arms), sponsored by Reindeer Biotech. Primary endpoint: Adverse Events at 25 weeks. Started May 2026; status: recruiting.
02
Drugs
IASO-782
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT07483346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07483346.